Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations.

IF 6.3 2区医学 Q2 IMMUNOLOGY

Inflammopharmacology Pub Date : 2026-10-01 Epub Date: 2026-09-17 DOI:10.1007/s10787-026-02397-x

Weihong Long, Caiyun Zhang, Can Zhang, Junjie Ni, Chao Xiong, Xu Wu, Mingxing Li, Fukuan Du, Yu Chen, Yueshui Zhao, Jing Shen, Chi Hin Cho, Zhangang Xiao

{"title":"Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations.","authors":"Weihong Long, Caiyun Zhang, Can Zhang, Junjie Ni, Chao Xiong, Xu Wu, Mingxing Li, Fukuan Du, Yu Chen, Yueshui Zhao, Jing Shen, Chi Hin Cho, Zhangang Xiao","doi":"10.1007/s10787-026-02397-x","DOIUrl":null,"url":null,"abstract":"<p><p>Ovarian cancer, one of the most prevalent and formidable malignant tumours within the female reproductive system, poses a grave threat to women's health and lives. Although the current standard-of-care treatments-including cytoreductive surgery and platinum-based chemotherapy, supplemented by maintenance therapy with anti-angiogenic agents and poly (ADP-ribose) polymerase (PARP) inhibitors, can alleviate the disease to a certain extent, they face significant limitations, such as resistance to chemotherapeutic drugs, toxicity to normal tissues, and recurrence of the tumour. In contrast, natural killer (NK) cells, as an important part of the body's immune system, have anti-tumour activities, and their interaction with ovarian cancer cells to kill ovarian cancer cells brings new hope for cell therapy. The aim of this paper is to summarize the mechanisms involved in NK cells in ovarian cancer treatment, the current status of clinical applications, and new research strategies in the future, with the aim of providing a reference for the development of research and clinical practice in this field.</p>","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"6413-6430"},"PeriodicalIF":6.3000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10787-026-02397-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Ovarian cancer, one of the most prevalent and formidable malignant tumours within the female reproductive system, poses a grave threat to women's health and lives. Although the current standard-of-care treatments-including cytoreductive surgery and platinum-based chemotherapy, supplemented by maintenance therapy with anti-angiogenic agents and poly (ADP-ribose) polymerase (PARP) inhibitors, can alleviate the disease to a certain extent, they face significant limitations, such as resistance to chemotherapeutic drugs, toxicity to normal tissues, and recurrence of the tumour. In contrast, natural killer (NK) cells, as an important part of the body's immune system, have anti-tumour activities, and their interaction with ovarian cancer cells to kill ovarian cancer cells brings new hope for cell therapy. The aim of this paper is to summarize the mechanisms involved in NK cells in ovarian cancer treatment, the current status of clinical applications, and new research strategies in the future, with the aim of providing a reference for the development of research and clinical practice in this field.

查看原文本刊更多论文

自然杀伤细胞在卵巢癌治疗：机制，逃避，和治疗创新。

卵巢癌是女性生殖系统内最普遍和最可怕的恶性肿瘤之一，对妇女的健康和生命构成严重威胁。虽然目前的标准治疗-包括细胞减少手术和铂基化疗，辅之以抗血管生成药物和多（adp -核糖）聚合酶（PARP）抑制剂的维持治疗-可以在一定程度上缓解疾病，但它们面临着明显的局限性，如对化疗药物的耐药性，对正常组织的毒性以及肿瘤的复发。相比之下，自然杀伤细胞（natural killer， NK）作为机体免疫系统的重要组成部分，具有抗肿瘤活性，与卵巢癌细胞相互作用杀灭卵巢癌细胞，为细胞治疗带来了新的希望。本文就NK细胞在卵巢癌治疗中的作用机制、临床应用现状及未来研究的新策略进行综述，以期为该领域的研究发展和临床实践提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Inflammopharmacology IMMUNOLOGYTOXICOLOGY-TOXICOLOGY

CiteScore

8.00

自引率

3.40%

发文量

200

期刊介绍： Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn''s disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas: -Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states -Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs -Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents -Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain -Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs -Muscle-immune interactions during inflammation [...]